Phase 1, Healthy Subject, Safety, Tolerability and Pharmacokinetic Study of mGlu5 NAM HTL0014242

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 14, 2018

Primary Completion Date

March 11, 2021

Study Completion Date

March 11, 2021

Conditions

Healthy

Interventions

DRUG

HTL0014242

HTL0014242 is a selective negative allosteric modulator (NAM) for the metabotropic glutamate (mGlu) receptor 5 subtype (mGlu5)

DRUG

Placebo oral capsule

Placebo treatment

Trial Locations (1)

Covance, Leeds